Kyverna Therapeutics (KYTX) Q2 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure
Key numbers
- Reported EPS
- —
- Estimate
- -$0.68
- Surprise
- —
- Score today
- 4.5/10
Revenue for this quarter isn’t shown: the reported figure hasn’t cleared TrendMatrix’s freshness and sanity checks yet, and consensus revenue isn’t tracked. EPS above is the available figure.
Coverage in the report window
- Kyverna Therapeutics Q2 EPS $(0.63) Beats $(0.68) Estimate — benzinga, 2026-08-11
Where TrendMatrix's rating stands now
TrendMatrix currently rates KYTX Sell at 4.5/10; no pre/post engine snapshot brackets this report.
4 of the last 4 quarters beat the estimate. Next scheduled report: 2026-11-11.
What argues against it
- Concentration risk — Pipeline: product candidates
- Concentration risk — Counterparty: National Institutes of Health (NIH)
- DATA_ISSUE: analyst_target_implausible (raw $30.40 vs price $6.90 — ratio 4.4×). Rejected, falling back to technical TP.
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $6.90
- Price target
- $8.96
- Stop
- $6.65
- Upside to target
- +29.9%
Risk check: RSI 19 — a level conventionally read as oversold.
Model outputs from TrendMatrix’s engine as of 2026-09-17 — shown for context, not personalized investment advice.
KYTX at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Biotechnology
- Market cap
- $430.4M
- P/E (fwd)
- -2.3
- 52-week range
- $3.95–$13.67
- Off 52-week high
- 49.5%
- RSI (14)
- 19
- Volume vs avg
- 0.95×
- Score today
- 4.5/10